Sanofi-aventis introduces sanofi-aventis TV "A window on our company"

sanofi-aventisSanofi-aventis (EURONEXT: SAN and NYSE: SNY) has announced the launch of sanofi-aventis TV, a new webTV aimed at providing information about the company's wide range of patient-focused businesses, social responsibilities, and employee activities. The site will also provide perspectives on the company's mission and strategic directions.

"As part of the company's overall goal to increase transparency and understanding of its operations inside and outside its walls, sanofi-aventis TV will be a continually updated source of interactive information," said Christopher A. Viebacher, Chief Executive Officer of sanofi-aventis. "This new means of communication is another example of the transformation process underway within sanofi-aventis," he added.

Available to everyone on the internet, sanofi-aventis TV is a new window onto the life of the company, its activities and commitments in all countries where the Group is present.

Through short, regularly updated videos, sanofi-aventis TV offers a wide variety of programmes and formats - interviews, profiles, reports - for its different audiences, including patients, healthcare professionals, Group employees, medias, financial analysts, and shareholders.

Sanofi-aventis TV, 6 themed channels are accessible at www.sanofi-aventis.tv

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...